Review



broad-panel respiratory mpcr filmarray pneumonia panel plus  (BioFire Defense)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    BioFire Defense broad-panel respiratory mpcr filmarray pneumonia panel plus
    Trial design. In the intervention arm, before the end of day 1, clinicians have to consider all the early microbiological results <t>(mPCR</t> FA-PPP, urine antigen assays, blood cultures and Gram stain examination of <t>respiratory</t> tract sample) and procalcitonin before the end of day 1, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation (red square). This algorithm is described in . In both arms, at day 3 and day after day until day 7, clinicians are encouraged to consider antibiotic discontinuation, based on procalcitonin values and kinetics. CAP, community-acquired pneumonia; FA-PPP, FilmArray Pneumonia Panel Plus; ICU, intensive care unit; mPCR, multiplex PCR.
    Broad Panel Respiratory Mpcr Filmarray Pneumonia Panel Plus, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/broad-panel respiratory mpcr filmarray pneumonia panel plus/product/BioFire Defense
    Average 90 stars, based on 1 article reviews
    broad-panel respiratory mpcr filmarray pneumonia panel plus - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units"

    Article Title: Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units

    Journal: BMJ Open

    doi: 10.1136/bmjopen-2020-048187

    Trial design. In the intervention arm, before the end of day 1, clinicians have to consider all the early microbiological results (mPCR FA-PPP, urine antigen assays, blood cultures and Gram stain examination of respiratory tract sample) and procalcitonin before the end of day 1, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation (red square). This algorithm is described in . In both arms, at day 3 and day after day until day 7, clinicians are encouraged to consider antibiotic discontinuation, based on procalcitonin values and kinetics. CAP, community-acquired pneumonia; FA-PPP, FilmArray Pneumonia Panel Plus; ICU, intensive care unit; mPCR, multiplex PCR.
    Figure Legend Snippet: Trial design. In the intervention arm, before the end of day 1, clinicians have to consider all the early microbiological results (mPCR FA-PPP, urine antigen assays, blood cultures and Gram stain examination of respiratory tract sample) and procalcitonin before the end of day 1, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation (red square). This algorithm is described in . In both arms, at day 3 and day after day until day 7, clinicians are encouraged to consider antibiotic discontinuation, based on procalcitonin values and kinetics. CAP, community-acquired pneumonia; FA-PPP, FilmArray Pneumonia Panel Plus; ICU, intensive care unit; mPCR, multiplex PCR.

    Techniques Used: Staining, Multiplex Assay

    Algorithm of early antibiotics de-escalation or discontinuation. The algorithm is applied in the intervention arm only (see red square, ). mPCR, multiplex PCR; ICU, intensive care unit; PCT, procalcitonin.
    Figure Legend Snippet: Algorithm of early antibiotics de-escalation or discontinuation. The algorithm is applied in the intervention arm only (see red square, ). mPCR, multiplex PCR; ICU, intensive care unit; PCT, procalcitonin.

    Techniques Used: Multiplex Assay

    Primary and secondary outcomes
    Figure Legend Snippet: Primary and secondary outcomes

    Techniques Used: Bacteria, Biomarker Discovery



    Similar Products

    broad-panel respiratory mpcr filmarray pneumonia panel plus  (BioFire Defense)
    90
    BioFire Defense broad-panel respiratory mpcr filmarray pneumonia panel plus
    Trial design. In the intervention arm, before the end of day 1, clinicians have to consider all the early microbiological results <t>(mPCR</t> FA-PPP, urine antigen assays, blood cultures and Gram stain examination of <t>respiratory</t> tract sample) and procalcitonin before the end of day 1, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation (red square). This algorithm is described in . In both arms, at day 3 and day after day until day 7, clinicians are encouraged to consider antibiotic discontinuation, based on procalcitonin values and kinetics. CAP, community-acquired pneumonia; FA-PPP, FilmArray Pneumonia Panel Plus; ICU, intensive care unit; mPCR, multiplex PCR.
    Broad Panel Respiratory Mpcr Filmarray Pneumonia Panel Plus, supplied by BioFire Defense, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/broad-panel respiratory mpcr filmarray pneumonia panel plus/product/BioFire Defense
    Average 90 stars, based on 1 article reviews
    broad-panel respiratory mpcr filmarray pneumonia panel plus - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Trial design. In the intervention arm, before the end of day 1, clinicians have to consider all the early microbiological results (mPCR FA-PPP, urine antigen assays, blood cultures and Gram stain examination of respiratory tract sample) and procalcitonin before the end of day 1, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation (red square). This algorithm is described in . In both arms, at day 3 and day after day until day 7, clinicians are encouraged to consider antibiotic discontinuation, based on procalcitonin values and kinetics. CAP, community-acquired pneumonia; FA-PPP, FilmArray Pneumonia Panel Plus; ICU, intensive care unit; mPCR, multiplex PCR.

    Journal: BMJ Open

    Article Title: Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units

    doi: 10.1136/bmjopen-2020-048187

    Figure Lengend Snippet: Trial design. In the intervention arm, before the end of day 1, clinicians have to consider all the early microbiological results (mPCR FA-PPP, urine antigen assays, blood cultures and Gram stain examination of respiratory tract sample) and procalcitonin before the end of day 1, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation (red square). This algorithm is described in . In both arms, at day 3 and day after day until day 7, clinicians are encouraged to consider antibiotic discontinuation, based on procalcitonin values and kinetics. CAP, community-acquired pneumonia; FA-PPP, FilmArray Pneumonia Panel Plus; ICU, intensive care unit; mPCR, multiplex PCR.

    Article Snippet: In the experimental strategy arm, the microbiological diagnosis combines a broad-panel respiratory mPCR (FilmArray Pneumonia Panel Plus (FA-PPP), BioFire Biomérieux) with conventional microbiological investigations.

    Techniques: Staining, Multiplex Assay

    Algorithm of early antibiotics de-escalation or discontinuation. The algorithm is applied in the intervention arm only (see red square, ). mPCR, multiplex PCR; ICU, intensive care unit; PCT, procalcitonin.

    Journal: BMJ Open

    Article Title: Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units

    doi: 10.1136/bmjopen-2020-048187

    Figure Lengend Snippet: Algorithm of early antibiotics de-escalation or discontinuation. The algorithm is applied in the intervention arm only (see red square, ). mPCR, multiplex PCR; ICU, intensive care unit; PCT, procalcitonin.

    Article Snippet: In the experimental strategy arm, the microbiological diagnosis combines a broad-panel respiratory mPCR (FilmArray Pneumonia Panel Plus (FA-PPP), BioFire Biomérieux) with conventional microbiological investigations.

    Techniques: Multiplex Assay

    Primary and secondary outcomes

    Journal: BMJ Open

    Article Title: Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units

    doi: 10.1136/bmjopen-2020-048187

    Figure Lengend Snippet: Primary and secondary outcomes

    Article Snippet: In the experimental strategy arm, the microbiological diagnosis combines a broad-panel respiratory mPCR (FilmArray Pneumonia Panel Plus (FA-PPP), BioFire Biomérieux) with conventional microbiological investigations.

    Techniques: Bacteria, Biomarker Discovery